Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02039986 · ClinicalTrials.gov registry record
Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)
A clinical trial, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- 13
- Enrollment target
NCT02039986: Completed study, sponsored by Children's Hospital of Philadelphia.
NCT02039986 is a clinical trial that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02039986 has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
This study is aimed at better understanding the impact of ivacaftor upon insulin and incretin secretion and glucose tolerance in patients with Cystic Fibrosis with a glycine (G551D) mutation. Investigators hypothesize that treatment with ivacaftor improves insulin secretion in individuals with CF.
Primary Outcome
To compare insulin secretion and maximal insulin secretory capacity prior to initiation of ivacaftor and after 16 weeks of ivacaftor treatment in subjects with CF and at least one G551D CFTR mutation, or other CFTR gating mutation, and to explore the impact of ivacaftor upon incretin secretion, incretin regulation of insulin secretion, and glucose excursion during a mixed meal tolerance test in CF.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2014-01-06 |
| Est. Completion | 2016-10-11 |
What the finished NCT02039986 record still lists
NCT02039986 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02039986 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02039986 about?
NCT02039986 is a clinical study titled "Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)". This study is aimed at better understanding the impact of ivacaftor upon insulin and incretin secretion and glucose tolerance in patients with Cystic Fibrosis with a glycine (G551D) mutation. Investigators hypothesize that treatment with ivacaftor improves insulin secretion in individuals with CF.
What is the current status of trial NCT02039986?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2014-01-06. Estimated completion is 2016-10-11.
Who is sponsoring clinical trial NCT02039986?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI